Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-acting exenatide for mild cognitive impairment
2015-001850-13Phase 2Completed
- Sponsor
- Azienda Ospedaliero-Universitaria di Parma
- Start
- Dec 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of exenatide in Mild Cognitive Impairment (MCI) (2 arms), sponsored by Azienda Ospedaliero-Universitaria di Parma. Primary endpoint: ADAS-Cog change at 16 and 32 weeks. Started Dec 2020; status: completed.
02
Drugs
exenatide
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on 2015-001850-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001850-13.